CD5L and hepatocellular carcinoma: A proteomic study on hepatocellular carcinoma identified a high expression of Jchain, together with Cd5l and Lgals3bp, which positively correlated with the response of the chemotherapeutic agent sorafenib (113); their downregulation during tumorigenesis was possibly due to the immunosuppressive effects of the tumour cells.